2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome - professional.heart.org
The AHA, ACC, ADA, and ASN have released new 2026 clinical guidelines for managing Cardiovascular-Kidney-Metabolic (CKM) syndrome. This document replaces previous obesity management guidelines to provide a unified, evidence-based framework for clinicians treating interconnected metabolic and cardiovascular conditions.
Why it matters
It establishes a new standard of care for chronic, interrelated diseases that affect a significant portion of the global population, shifting from siloed treatment to integrated management.
AIM The “2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome” retires, replaces, and expands upon the “2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults.” The primary intended audience for this guideline is clinicians who care for patients across the spectrum of cardiovascular-kidney-metabolic syndrome, an interrelated condition characterized by the interconnections among metabolic risk factors (including obesity and type 2 diabetes), chronic kidney disease, and cardiovascular disease.
The content is a factual summary of a medical guideline publication without political or social commentary.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in